晚发性慢性荨麻疹中的体细胞嵌合NLRP3突变与炎症小体活化
本研究对两名60岁以上、病程约二十年且对标准治疗抵抗的慢性荨麻疹患者进行靶向测序,发现二者均携带体细胞嵌合NLRP3突变,且突变不限于髓单核细胞,提示突变发生于胚胎早期。功能研究显示突变对NLRP3炎症小体活化具有功能获得效应,抗IL-1受体拮抗剂使两例患者均获完全缓解。
要点
- 晚发性难治性慢性荨麻疹应排查自身炎症标志物及体细胞嵌合NLRP3突变。
- NLRP3嵌合突变可累及非髓单核细胞,提示胚胎早期即发生突变事件。
- 抗IL-1受体拮抗剂可使携带NLRP3嵌合突变的患者获得完全缓解。
核心结论
- 晚发性慢性荨麻疹中,体细胞嵌合NLRP3突变及自身炎症标志物的检测可能具有重要诊断和治疗意义。
研究设计与样本
- 研究纳入两名60岁以上、表现为约二十年慢性荨麻疹且对标准治疗抵抗、伴非寒冷触发的系统性炎症的患者。
- 采用下一代测序技术的靶向测序方法鉴定突变,并对患者多种细胞类型及突变功能进行研究。
主要发现
- 两名患者均检出NLRP3体细胞嵌合突变,分别为一个框内缺失和一个复发性NLRP3错义突变。
- 尽管疾病晚发,NLRP3突变并未局限于髓单核细胞,数据强烈提示突变事件发生于胚胎发育早期。
- 功能研究显示所鉴定突变对NLRP3炎症小体活化具有功能获得效应。
- 两例患者在接受抗IL-1受体拮抗剂治疗后均获得完全缓解。
关键数值与推荐
- 两名患者年龄均超过60岁,慢性荨麻疹病程约二十年,且对标准治疗抵抗。
临床怎么用
- 对晚发性、难治性慢性荨麻疹,可考虑检测自身炎症标志物及体细胞嵌合NLRP3突变。
- 若发现NLRP3嵌合突变伴炎症小体活化,抗IL-1受体拮抗剂可能实现完全缓解。
局限性
- 研究仅基于两名患者,结论的外推需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic urticaria is a common skin disorder with heterogeneous causes. In the absence of physical triggers, chronic urticarial rash is called idiopathic or spontaneous. The objective of this study was to identify the molecular and cellular bases of a disease condition displayed by two unrelated patients aged over 60 years who presented for two decades with a chronic urticaria resistant to standard therapy that occurred in the context of systemic inflammation not triggered by cold. In both patients, a targeted sequencing approach using a next generation technology identified somatic mosaic mutations in NLRP3, a gene encoding a key inflammasome component. The study of several of both patients' cell types showed that, despite the late onset of the disease, NLRP3 mutations were not found to be restricted to myelomonocytic cells. Rather, the data obtained strongly suggested that the mutational event occurred very early, during embryonic development. As shown by functional studies, the identified mutations-an in-frame deletion and a recurrent NLRP3 missense mutation-have a gain-of-function effect on NLRP3-inflammasome activation. Consistently, a complete remission was obtained in both patients with anti-IL-1 receptor antagonists. This study unveils that in late-onset chronic urticaria, the search for autoinflammatory markers and somatic mosaic NLRP3 mutations may have important diagnostic and therapeutic consequences.
引用
- Assrawi E, Louvrier C, Lepelletier C, et al. Somatic Mosaic NLRP3 Mutations and Inflammasome Activation in Late-Onset Chronic Urticaria. J Invest Dermatol. 2019. PMID: 31513803. doi:10.1016/j.jid.2019.06.153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。